What to expect from Lupus Science and Medicine
BMJ GroupEpisode Description
More Episodes
-
0Use of Artificial Intelligence and Machine Learning in Clinical Practice
-
0To RNase or Not to RNase: That Is the Question
-
0A decision-aid facilitates patient understanding of benefits vs. risk of hydroxychloriquine use as part of routine care for lupus
-
0Dual dsDNA testing may be needed to fully understand patient disease status
-
0Is Anifrolumab an effective treatment for lupus nephritis?
-
0Which one is better at controlling lupus: Belimumab or Anifrolumab?
-
0Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis
-
0Testing a new measure of lupus improvement that encompasses the patients’ perspectives and doctors’ evaluations
-
0Understanding Lupus: Exploring the Differences between Type 1 and Type 2 Symptoms
-
0Unpacking Lupus Treatment: How Quickly Does Anifrolumab Start Working? Insights from TULIP Trials
-
0Biomarker reduction indicates treatment response to Belimumab
-
0Mesenchymal stromal cells: a potential new SLE treatment option?
-
0Using patient registries to estimate SLE incidence rate in the USA
-
0Defining remission in systemic lupus erythematosus
-
0What’s the relationship between self-efficacy and quality of life in SLE patients?
-
0Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE
-
0Could a high fiber diet positively impact the gut microbiome of SLE patients?
-
0A new biomarker for cognitive dysfunction in SLE?
-
0Screening for cognitive dysfunction in SLE patients
-
0Highlights of ACR Convergence 2021
-
0Personalised metabolite monitoring during pre-conception and pregnancy in SLE patients
-
0Can you predict lupus nephritis outcomes using machine learning models?
-
0Highlights of the LUPUS & CORA 2021 joint congress
-
0Identifying therapeutic targets in lupus nephritis: is obtaining research tissue via biopsy safe?
-
0LSM’s first Journal Impact Factor™
-
0Can you conduct clinical trials on lupus patients in a home setting?
-
0EULAR 2021 eCongress Highlights
-
0Safety profile of anifrolumab in SLE patients
-
0The ALPHA Project
-
0Lupus Academy 10th Annual Meeting Highlights
-
0Lupus Academy Tenth Annual Meeting Preview
-
0Apolipoprotein L1 risk genotypes in Ghanaian patients
-
0Anti-Müllerian hormone in African- American women with SLE
-
0Efficacy and safety of rituximab biosimilar in refractory lupus
-
0Metabolic syndrome in SLE patients
-
0Validating the use of LFA-REAL to measure disease severity in SLE
-
0ANA testing in SLE and autoimmune rheumatic diseases
-
0Kynurenine pathway is altered in patients with SLE and associated with severe fatigue
-
0TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
-
0Lupus Science & Medicine: what makes it special?
-
0Anifrolumab effects on rash and arthritis
-
0COVID-19 Impact on people with lupus
-
0Lupus, immunity and Covid-19 - Part 2
-
0Immunity for lupus patients and effects of Covid-19 - Part 1
-
0Education and the latest in treatment: reporting from the Lupus Academy 2017
-
0Lupus Science and Medicine first year anniversary
-
0BMJ and the Lupus Foundation of America announce the first open access lupus scientific journal
Comments (0)
0/500
New Comments(0)
What do you think of this episode?